Ziconotide

• Autores: M.A. Vidal , Luis Miguel Torres Morera
• Localización: Revista de la Sociedad Española del Dolor (SED), ISSN 1134-8046, Vol. 13, Nº. 4, 2006, págs. 263-264
• Idioma: español
• Enlaces
  • Texto completo (pdf)
• Referencias bibliográficas
  • Wermeling, DP, Berger, JR. (2006). Ziconotide infusion for severe chronic pain: cases series of patients with neuropathic pain. J Biophys...
  • Heading, CE. (2005). Ziconotide (Elan Pharmaceuticals). Br J Pharmacol,. 145. 728
  • Snutch, TP. (2005). Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. Am J Hosp Palliat Care. 22. 369
  • Wang, F, Chen, G, Zhu, Y. (2005). Development of antibody-based assays for omega-conotoxin MVIIA. NeuroRx. 662-670
  • Bowersox, SS, Gadbois, T, Singh, T. (1996). Selective N-type neuronal voltage sensitive calcium channel bloc-ker, SNX-111, produces spinal...
  • Staats, PS, Yearwood, T, Charapata, SG. (2004). Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS....
  • Jain, KK. (2000). An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin Investig Drugs. 9. 2403
  • Webster, L, Henderson, R, Katz, N. (2001). Characterization of confusion, an adverse event associated with intrathecal ziconotide infusión...
  • Penn, RD, Paice, JA. (2000). Adverse effects associated with the intrathecal administration of ziconotide. Pain. 85. 291-296
  • Wermeling, DP. (2005). Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy....